Cooperation of activating Ras/rtk signal transduction pathway mutations and inactivating myeloid differentiation gene mutations in M0 AML: a study of 45 patients

[1]  S. Meshinchi,et al.  Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia , 2005, Leukemia.

[2]  H. Mitsuya,et al.  Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22) , 2005, Leukemia.

[3]  Zang Ai-hua,et al.  Stem Cells,Cancer and Cancer Stem Cells , 2005 .

[4]  John D. Minna,et al.  Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia , 2004, Cancer Research.

[5]  M. Taniwaki,et al.  Novel loss‐of‐function mutations of the haematopoiesis‐related transcription factor, acute myeloid leukaemia 1/runt‐related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome , 2004, British journal of haematology.

[6]  A. Aventín,et al.  FLT3 mutations are associated with other molecular lesions in AML. , 2004, Leukemia research.

[7]  T. Naoe,et al.  Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype , 2003, Leukemia.

[8]  Natalia Meani,et al.  Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. , 2003, The Journal of clinical investigation.

[9]  I. Bernstein,et al.  Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. , 2003, Blood.

[10]  J. Reilly,et al.  Incidence and prognosis of c‐KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias , 2003, British journal of haematology.

[11]  J. Licht,et al.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia , 2003, Nature Genetics.

[12]  O. Casasnovas,et al.  M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Français d'Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH). , 2003, Blood.

[13]  C. Preudhomme,et al.  New mechanisms of AML1 gene alteration in hematological malignancies , 2003, Leukemia.

[14]  C. Preudhomme,et al.  Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)? , 2002, Blood.

[15]  J. Griffin,et al.  The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.

[16]  J. Downing.  AML1/CBFβ transcription complex: its role in normal hematopoiesis and leukemia , 2001, Leukemia.

[17]  D. Gilliland,et al.  Molecular genetics of acute myeloid leukaemia. , 2001, Best practice & research. Clinical haematology.

[18]  E. Macintyre,et al.  High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. , 2000, Blood.

[19]  S. Hiebert,et al.  Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. , 2000, Gene.

[20]  John M. Maris,et al.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia , 1999, Nature Genetics.

[21]  T. Naoe,et al.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. , 1999, Blood.

[22]  M. Tribalto,et al.  Minimally differentiated acute myeloid leukemia (AML-MO): a distinct clinico-biologic entity with poor prognosis , 1996, Annals of Hematology.

[23]  E. Paietta.  Proposals for the immunological classification of acute leukemias. , 1995, Leukemia.

[24]  A Orfao,et al.  Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.

[25]  J. Testa,et al.  Minimally differentiated acute nonlymphocytic leukemia: a distinct entity. , 1987, Blood.